Augmented hepatic PTEN and reduced systemic FGF21 levels, in turn, perturbed hepatic as well as systemic insulin sensitivity, leading to basal hyperinsulinemia and impaired glucose tolerance. The gene discussed is PTEN; the disease is hyperinsulinism.